- Home
- TPST vs GDTC Comparison
TPST vs GDTC Comparison
Compare TPST & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- GDTC
- Stock Information
- Founded
- TPST 2011
- GDTC 2018
- Country
- TPST United States
- GDTC Singapore
- Employees
- TPST N/A
- GDTC N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- GDTC Health Care
- Exchange
- TPST Nasdaq
- GDTC Nasdaq
- Market Cap
- TPST 33.0M
- GDTC 21.5M
- IPO Year
- TPST N/A
- GDTC 2023
- Fundamental
- Price
- TPST $7.54
- GDTC $1.89
- Analyst Decision
- TPST Hold
- GDTC Buy
- Analyst Count
- TPST 3
- GDTC 1
- Target Price
- TPST $30.00
- GDTC $5.00
- AVG Volume (30 Days)
- TPST 94.0K
- GDTC 18.1K
- Earning Date
- TPST 08-11-2025
- GDTC 01-01-0001
- Dividend Yield
- TPST N/A
- GDTC N/A
- EPS Growth
- TPST N/A
- GDTC N/A
- EPS
- TPST N/A
- GDTC N/A
- Revenue
- TPST N/A
- GDTC $368,838.00
- Revenue This Year
- TPST N/A
- GDTC $5.37
- Revenue Next Year
- TPST N/A
- GDTC N/A
- P/E Ratio
- TPST N/A
- GDTC N/A
- Revenue Growth
- TPST N/A
- GDTC N/A
- 52 Week Low
- TPST $5.35
- GDTC $1.20
- 52 Week High
- TPST $28.34
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- TPST 56.78
- GDTC 37.08
- Support Level
- TPST $7.13
- GDTC $1.85
- Resistance Level
- TPST $8.75
- GDTC $1.95
- Average True Range (ATR)
- TPST 0.47
- GDTC 0.10
- MACD
- TPST 0.12
- GDTC -0.02
- Stochastic Oscillator
- TPST 54.17
- GDTC 28.00
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.